Navigation Links
Photonic Products Group, Inc. Reports Record Financial Results for FY 2007
Date:3/31/2008

NORTHVALE, N.J., March 31 /PRNewswire-FirstCall/ -- Photonic Products Group, Inc. (PHPG) today reported its consolidated, audited, financial results for its fiscal year which ended December 31, 2007.

Revenues in fiscal year 2007 were a record at $15,100,000 up 8.5% compared with $13,921,000 last year. Order intake for the year was our highest ever at $17,802,000 as was our year-end backlog of $9,672,000, up 34.0% and 38.4% from 2006, respectively.

Pre-tax income for the year was $2,130,000 compared to $793,000 in 2006, up 169%. Net income in 2007 was $1,880,000, after an income tax provision of $250,000. Net income in 2006 was $772,000, after an income tax provision of $21,000.

Gross profit of $5,959,000 was up 31% from $4,544,000 in 2006, as gross profit margin for the year improved to 39.5% from 32.6%. Income from operations increased to $2,397,000, up 161% from last year's $917,000.

Basic and diluted earnings per share, after accounting for the common stock dividend on preferred stock, were $0.19 and $0.13, respectively, in 2007, compared with basic and diluted EPS of $0.07 and $0.06, respectively in 2006.

Net cash flow from operating activities was $3,001,000 for the year, compared with $2,672,000 in 2006. For 2007, cash and cash equivalents increased $1,318,000 to $4,396,000 at year-end, after net cash outlays for debt repayments and redemptions of $1,893,000, and a decrease of $117,000 in customer advances. In 2006, cash and cash equivalents increased by $1,921,000, including net borrowings of $373,000 and an increase of $336,000 in customer advances, to $3,078,000 at year-end.

EBITDA(1) for the year rose to $3,545,000, up from $2,412,000 in 2006 and $1,485,000 in 2005.

The Company reported fourth quarter revenues of $4,042,000 this year, compared with revenues of $3,678,000 in the same period, a year ago. Pre-tax net income was $421,000 vs. $412,000 in the same period last year, the Company's tenth conse
'/>"/>

SOURCE Photonic Products Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Professor Straufs research is Nature Photonics’ cover article
2. 3-D photonic crystals will revolutionize telecommunications
3. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
4. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
5. Live Demos With Hydrogen, New Fuel Cell Products
6. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
7. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
8. iCAD to Feature New Products and Capabilities at European Congress of Radiology
9. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
10. China Biologic Products Commences Trading on OTC Bulletin Board
11. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
(Date:12/19/2014)... 2014 Reports from CDC ... suffer from one or more chronic health conditions - ... can address some of these diseases, but may not ... sufferers face. While implanted nerve stimulation devices today offer ... nerve, which can induce side effects. , To ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced the results ... "This was a transformational year in Relmada,s ... future for our company," said Sergio Traversa , ... we have executed on key financial, human resource and ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... II Study Shows 71% Objective Tumor Response Rate in Evaluable ... Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free ... Fla. and TUSTIN, Calif., June 1 Peregrine Pharmaceuticals, Inc. ... from a Phase II trial of its lead anti-phosphatidylserine antibody ...
... CHICAGO, June 1 UCB, Inc. and the ... of the 2009 Research Awards in Inflammatory Bowel Disease (IBD) ... research grant for their original clinical or basic research, totaling ... the CDWG Steering Committee and the awards were funded by ...
... today that promising results from ongoing clinical studies in prostate, ... AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society ... Orlando, Florida. , , (Logo: ... , "We are delighted with the depth and breadth ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... in the rich tapestry of biochemical signals that cause ... dramatically killed brain cancer cells by blocking those signals ... The unlikely pairing of cholesterol-lowering lovastatin and cyclopamine killed ... By contrast, using either agent alone wiped out ...
... detection of base sequence in duplex nucleic acid has ... "Heteropolymeric Triplex-Based Genomic Assay® to Detect Pathogens or Single-Nucleotide ... issue of the international, peer-reviewed, open access, online journal, ... a wealth of data relating to the assay of ...
... Baylor College of Medicine have discovered a new way to ... to enter cancer cells. , The research appears in the ... , All living cells defend themselves by walling off ... cocoon around the cell's inner machinery and its DNA blueprints. ...
Cached Biology News:Statin plus cancer drug deliver combo punch to brain cancer cells 2Triplex assay used to assay duplex genomic DNA 2Buckyballs used as 'passkey' into cancer cells 2
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Biology Products: